Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound-Reference-Cited by-同舟云学术

Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound

Published:2020-05-18 Issue:6 Volume:130 Page:3299-3304
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Cale Evan M.,Bai Hongjun^ORCID,Bose Meera^ORCID,Messina Michael A.,Colby Donn J.,Sanders-Buell Eric^ORCID,Dearlove Bethany,Li Yifan,Engeman Emily,Silas Daniel,O’Sullivan Anne Marie^ORCID,Mann Brendan^ORCID,Pinyakorn Suteeraporn^ORCID,Intasan Jintana,Benjapornpong Khunthalee,Sacdalan Carlo^ORCID,Kroon Eugène,Phanuphak Nittaya^ORCID,Gramzinski Robert^ORCID,Vasan Sandhya^ORCID,Robb Merlin L.^ORCID,Michael Nelson L.^ORCID,Lynch Rebecca M.^ORCID,Bailer Robert T.,Pagliuzza Amélie,Chomont Nicolas^ORCID,Pegu Amarendra^ORCID,Doria-Rose Nicole A.^ORCID,Trautmann Lydie^ORCID,Crowell Trevor A.^ORCID,Mascola John R.,Ananworanich Jintanat^ORCID,Tovanabutra Sodsai,Rolland Morgane

Funder

cooperative agreement between The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and the U.S. Department of the Army

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://www.jci.org/articles/view/134395/files/pdf

Reference23 articles.

1. Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial

2. Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults

3. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection